Prevention of congenital abnormalities by vitamin A.
The objective of the study was to determine the human teratogenic risk of vitamin A supplementation during pregnancy. Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1994. Of 35,727 pregnant women who had control infants without defects, 3399 (9.5%) were treated with vitamin A. Of 20,830 pregnant women who had case offspring with congenital abnormalities, 1642 (7.9%) were treated with vitamin A, a rate that is significantly lower than that of the control group (p < 0.001). The case-control pair analysis also showed a lower rate of vitamin A treatment during pregnancy and in the first trimester of gestation in most congenital abnormality groups. Thus, use of low or moderate doses of vitamin A (< 10,000 IU) during the first trimester of pregnancy (i.e., organogenesis) is not teratogenic but presents some protective effect to the fetus.
Czeizel
A E
AE
Department of Human Genetics and Teratology, National Institute of Public Health, WHO Collaborating Centre for the Community Control of Hereditary Diseases, Budapest.
Rockenbauer
M
M
D000014:Abnormalities, Drug-Induced; D016022:Case-Control Studies; D000013:Congenital Abnormalities / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005865:Gestational Age; D006801:Humans; D006814:Hungary; D007231:Infant, Newborn; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D014801:Vitamin A / Q000008:administration & dosage* / Q000009:adverse effects*
D014801:Vitamin A